Selective COX-2 Inhibitors Reduce Gastrointestinal Ulcers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-steroidal anti-inflammatory drugs (NSAIDs) have limitations, including gastrointestinal side effects due to non-selective inhibition of COX-1 and COX-2 enzymes, leading to issues like stomach ulcers and bleeding, necessitating the development of selective NSAIDs with reduced frequency and severity of negative side effects.
Innovation Solution
Development of compounds (Compound 1 and Compound 2) that selectively inhibit COX-2 enzymes with a high selectivity index, minimizing inhibition of COX-1, thereby reducing gastrointestinal adverse effects, and administered orally to treat inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes, then inflammation is reduced effectively, but gastrointestinal side effects such as stomach ulcers and bleeding occur
Solution Approach 1:
The invention segments the COX enzyme inhibition function by designing compounds that selectively target COX-2 while sparing COX-1. This is achieved through molecular structure optimization that exploits the structural differences between COX-1 and COX-2 active sites, allowing selective binding to COX-2 and thereby resolving the contradiction between anti-inflammatory efficacy and gastrointestinal safety
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular characteristics that interact differently with COX-1 and COX-2 enzymes. The compounds possess structural features (such as substituted phenyl rings, heterocyclic groups, and specific functional groups) that provide preferential affinity for COX-2, enabling selective inhibition at the molecular level while maintaining therapeutic effectiveness
2Object-affected harmful factors
If selective COX-2 inhibitors are developed, then gastrointestinal ulcerogenic properties are decreased, but the compounds must maintain high selectivity index to ensure safety
Solution Approach 1:
The invention employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and electronic properties to optimize the selectivity index. By adjusting these chemical parameters, the compounds achieve high COX-2 selectivity (IC50 ratio of COX-1/COX-2 greater than 10) while maintaining potent anti-inflammatory activity, thereby resolving the contradiction between safety and selectivity precision
3Object-affected harmful factors
If new selective NSAID compounds are developed, then frequency and severity of negative side effects are reduced, but compound structure complexity increases
Solution Approach 1:
The invention uses local quality modifications by introducing specific functional groups and substituents at particular positions on the core molecular structure. These localized structural changes provide the necessary selectivity for COX-2 inhibition while keeping the overall molecular framework relatively simple and drug-like, thus balancing safety improvement with structural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively reduce inflammatory cell infiltration, alleviate edema, and show no adverse effects on gastric mucosa integrity or collagen content, demonstrating potential as new anti-inflammatory medicines with improved safety profiles.
Implementation Method 1
NSAIDs block cyclooxygenase (COX) enzymes, which are involved in formation of prostaglandins. Inhibition of COX enzymes impairs or inhibits prostaglandin synthesis, resulting in reduction of inflammation and in associated effects of inflammation.
Implementation Method 2
Prostaglandin E2 (PGE2) and prostaglandin 12 (PGI2, or prostacyclin) increase blood flow in inflamed areas by their potent vasodilators action.
Implementation Method 3
The vasodilation effect of Prostaglandin E2 and Prostacyclin 12 acts to protect the gastric mucosa by increasing the secretion of mucus and preventing increase of acidity and pepsin content in the stomach.
Implementation Method 4
COX-1 is expressed predominantly in the gastrointestinal tract, while COX-2 is predominantly produced at sites of inflammation. The stomach lining and renal functions are protected by certain prostaglandins produced by COX-1.
Implementation Method 5
The enzyme 5-lox is involved in transforming essential fatty acid substrates into leukotrienes (as well as other biologically active products). Leukotrienes (LTs) are the first class of mediators that contribute to the inflammatory process.
Implementation Method 6
In addition to lowering inflammation, however, non-selective medications inhibit platelet aggregation.
Data Source
AI summary
A method of treating inflammation includes administering an anti-inflammatory agent to a patient in need thereof. The anti-inflammatory agent is selected from Compound 1 ([(2-{[3-(4-methyl-1H-benzimidazol-2-yl)piperidin-1-yl]carbonyl}phenyl) amino] acetic acid) and Compound 2 (Ethyl-1-(5-cyano-2-hydroxyphenyl)-4-oxo-5-phenoxy-1,4-dihydropyridine-3-carboxylate). Compound 1 and Compound 2 selectively inhibit COX-2 enzyme, without substantially inhibiting COX-1 enzyme, in contrast to many other NSAIDs.